Alzheimer s Disease study: Methylphenidate
Official title Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia
ClinicalTrials.gov ID: NCT07279740
What this study is testing
What is Methylphenidate?
an investigational oral medication being studied as a potential treatment for apathy in Alzheimer's disease (or mixed AD/vascular dementia). is designed to increase dopamine and norepinephrine activity in the brain by blocking their reuptake.
Also referred to as Ritalin, Concerta.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to find out if combining a medication called methylphenidate with a painless brain stimulation technique can improve apathy (lack of interest or motivation).
- Who it's for
- This study is looking for adults who have Alzheimer's disease or a mix of Alzheimer's and vascular dementia and are experiencing apathy.
- What's involved
- Participants will receive methylphenidate and intermittent theta burst stimulation, which is a non-invasive method that uses magnetic fields to stimulate specific areas of the brain.
- Time commitment
- The source text does not specify the total duration of the study or the number of visits required.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Adults
You may be able to join if
- Alzheimer's disease or mixed Alzheimer's disease and vascular disease
- MMSE score 10-28 inclusive
- Clinically significant apathy
- Stable dose of psychotropic medication
- Care partner must spend at least 10hrs/week with the participant
You likely can't join if
- Major Depressive Episode
- Clinically significant agitation, delusions, hallucinations
- Currently talking a dopaminergic agent other than methylphenidate
- Failure to clear the TMS adult safety scale (e.g. unapproved pacemakers, metallic implants, history of epilepsy)
- Central nervous system abnormalities (other than Alzheimer's disease) deemed clinically significant by study physician or seizures
- Any condition that in the opinion of the study physician, makes it medically unsafe for the patient to enroll in the trial
The study team makes the final eligibility decision.
Where it is enrolling
- Toronto, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, not specified. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Toronto, Ontario, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.